Is the treatment of myasthenia gravis improving?
- 22 September 2020
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 95 (12), 509-510
- https://doi.org/10.1212/wnl.0000000000010578
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Patient-acceptable symptom states in myasthenia gravisNeurology, 2020
- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort studyThe Lancet Neurology, 2020
- Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre studyThe Lancet Neurology, 2017
- Randomized Trial of Thymectomy in Myasthenia GravisThe New England Journal of Medicine, 2016
- International consensus guidance for management of myasthenia gravisNeurology, 2016
- An up-date on health-related quality of life in myasthenia gravis -results from population based cohortsHealth and Quality of Life Outcomes, 2015
- Autoimmune myasthenia gravis: emerging clinical and biological heterogeneityThe Lancet Neurology, 2009
- An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravisNeurology, 2008
- Fatalities in Myasthenia GravisNeurology, 1956